• First-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globally
• This new study builds on the Phase III INBUILD® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3
• Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries
INGELHEIM, Germany-Wednesday 12 August 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult
Read more »